170 related articles for article (PubMed ID: 23902245)
41. New therapeutic agents for castration-refractory prostate cancer.
Patten DY; Sartor O
Clin Genitourin Cancer; 2009 Aug; 7(2):E4-6. PubMed ID: 19692323
[No Abstract] [Full Text] [Related]
42. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
Antonarakis ES; Drake CG
Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
[TBL] [Abstract][Full Text] [Related]
43. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
[TBL] [Abstract][Full Text] [Related]
44. Advances in the management of castration resistant prostate cancer.
Ritch CR; Cookson MS
BMJ; 2016 Oct; 355():i4405. PubMed ID: 27754846
[TBL] [Abstract][Full Text] [Related]
45. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Courtney KD; Taplin ME
Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
[TBL] [Abstract][Full Text] [Related]
46. [Management of enzalutamide, a new hormonal therapy].
Beuzeboc P; Benderra MA; de La Motte Rouge T
Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
[TBL] [Abstract][Full Text] [Related]
47. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
48. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.
Arlen PM
Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469
[No Abstract] [Full Text] [Related]
49. Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer.
Tsao PA; Caram MEV
Cancer J; 2020; 26(1):76-82. PubMed ID: 31977389
[TBL] [Abstract][Full Text] [Related]
50. The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.
Szucs TD; Puri D; Blank PR
Eur J Clin Pharmacol; 2014 Aug; 70(8):983-90. PubMed ID: 24858824
[TBL] [Abstract][Full Text] [Related]
51. New treatment options for patients with metastatic castration-resistant prostate cancer.
Higano CS
Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
[TBL] [Abstract][Full Text] [Related]
52. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
[TBL] [Abstract][Full Text] [Related]
53. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
54. New treatment options for castration-resistant prostate cancer.
Simondsen K; Kolesar J
Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
[TBL] [Abstract][Full Text] [Related]
55. Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Nevedomskaya E; Baumgart SJ; Haendler B
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734647
[TBL] [Abstract][Full Text] [Related]
56. New options for the management of castration-resistant prostate cancer: a case perspective.
Goetz D
J Natl Compr Canc Netw; 2011 Feb; 9 Suppl 3():S13-23; quiz S24. PubMed ID: 21357663
[TBL] [Abstract][Full Text] [Related]
57. Novel therapies for metastatic castrate-resistant prostate cancer.
Dayyani F; Gallick GE; Logothetis CJ; Corn PG
J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
[TBL] [Abstract][Full Text] [Related]
58. New agents for the management of castration-resistant prostate cancer.
Cersosimo RJ
Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
[TBL] [Abstract][Full Text] [Related]
59. [Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].
Brodszky V; Péntek M; Baji P; Rencz F; Géczi L; Szûcs M; Berczi C; Gulácsi L
Magy Onkol; 2014 Sep; 58(3):189-97. PubMed ID: 25260083
[TBL] [Abstract][Full Text] [Related]
60. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]